| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xin Wang, Wei-Hu Wang, Shu-Lian Wang, Yong-Wen Song, Yue-Ping Liu, Yuan Tang, Ning Li, Wen-Yang Liu, Hui Fang, Ye-Xiong Li, Dong-Bing Zhao, Yihebali Chi, Lin Yang and Jing Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Hope Run Special Fund of Cancer Foundation of China |
LC2018L03 |
| Sanming Project of Medicine in Shenzhen |
SZSM201612063 |
| Shenzhen High-level Hospital Construction Fund |
|
|
| Corresponding Author |
Jing Jin, MD, Doctor, Professor, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 113 Baohe Avenue, Longgang District, Shenzhen 518116, Guangdong Province, China. jingjin1025@163.com |
| Key Words |
Gastric cancer; Radiotherapy; Chemoradiotherapy; Clinical trial; Phase II |
| Core Tip |
In our previous phase I study, we found out adjuvant chemoradiotherapy (ACRT) regimen of 45 Gy radiotherapy concurrent with oral capecitabine was well tolerated in patients with locally advanced gastric cancer who had received partial or total gastrectomy. The maximum tolerated dose and recommended dose of capecitabine was 800 mg/m2 twice daily with oral administration. We performed this phase II study to further assess the efficacy and toxicity of this ACRT regimen as an adjuvant therapy after radical resection and D1/D2 lymph node dissection for locally advanced gastric cancer patients. |
| Publish Date |
2021-10-13 12:57 |
| Citation |
Wang X, Wang WH, Wang SL, Song YW, Liu YP, Tang Y, Li N, Liu WY, Fang H, Li YX, Zhao DB, Chi Y, Yang L, Jin J. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World J Gastrointest Oncol 2021; 13(10): 1532-1543 |
| URL |
https://www.wjgnet.com/1948-5204/full/v13/i10/1532.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v13.i10.1532 |
